Edgar Filing: Sage Therapeutics, Inc. - Form 4

Sage Therap	eutics, Inc.											
Form 4 August 04, 2	2015											
	ЛЛ								OMB AF	PROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287			
	Check this box if no longer CTLATED (ENTER OF CHANGES IN DEDEDICIAL ON DEDICIDED OF							Expires:	January 31, 2005			
subject to Section 1 Form 4 c	GES IN I SECUR		ICIA	LOWI	NERSHIP OF	Estimated a burden hour response	average Irs per					
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940												
(Print or Type]	Responses)											
PAUL STEVEN M Symbol				r Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer				
(Last) (First) (Middle) 3. Date of				Earliest Tr	ansaction			(Check all applicable)				
C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET(Month/E 08/03/2)				-				Director 10% Owner Officer (give title Other (specify below)				
				ndment, Date Original th/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 				
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	ecurity (Month/Day/Year) Execution Date, if			3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or				5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
				Code V	Amount		Price	(Instr. 3 and 4)				
Common Stock	08/03/2015			S <u>(1)</u>	4,822	D	\$ 67.98 (2)	718,828	D			
Common Stock	08/03/2015			S <u>(1)</u>	9,158	D	\$ 67.05 (3)	709,670	D			
Common Stock	08/03/2015			S <u>(1)</u>	6,020	D	\$ 66.42 (4)	703,650	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. ofNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Title Amoun Underl Securit (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

PAUL STEVEN M C/O SAGE THERAPEUTICS, INC. **215 FIRST STREET** CAMBRIDGE, MA 02142

Signatures

/s/ Laurie Burlingame, as Attorney-in-Fact for Steven M. Paul

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange (1)Act of 1934, as amended.
- This transaction was executed in multiple trades at prices ranging from \$67.60 USD to \$68.595 USD. The price reported above reflects (2) the weighted average sale price.
- This transaction was executed in multiple trades at prices ranging from \$66.62 USD to \$67.59 USD. The price reported above reflects the (3)weighted average sale price.
- This transaction was executed in multiple trades at prices ranging from \$66.00 USD to \$66.58 USD. The price reported above reflects the (4) weighted average sale price.

08/04/2015

Date

Edgar Filing: Sage Therapeutics, Inc. - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.